| SURMOUNT-MMOA Study of Tirzepatide (LY3298176) on the Reduction on Morbidity and Mortality in Adults With Obesity | Tirzepatide Obesity / overweight | BMI ≥27 · Established CVD | Ph 3 | Active, not recruiting | 671 | Oct 2027 | 1 | |
| SURPASS-CVOTA Study of Tirzepatide (LY3298176) Compared With Dulaglutide on Major Cardiovascular Events in Participants With Type 2 Diabetes | Dulaglutide, Tirzepatide Cardiovascular disease, Type 2 diabetes | BMI ≥25 · Established CVD | Ph 3 | Completed | 635 | Jun 2025 | 4 | |
| NCT07165028A Master Protocol of Multiple Agents in Adults With Metabolic Dysfunction-Associated Steatotic Liver Disease (SYNERGY-Outcomes) | Retatrutide, Tirzepatide MASH / NAFLD / liver fibrosis, Obesity / overweight | — | Ph 3 | Recruiting | 562 | Aug 2030 | — | |
| SURPASS-4A Study of Tirzepatide (LY3298176) Once a Week Versus Insulin Glargine Once a Day in Participants With Type 2 Diabetes and Increased Cardiovascular Risk | Tirzepatide Cardiovascular disease, Type 2 diabetes | BMI ≥25 | Ph 3 | Completed | 216 | Jan 2021 | 6 | results |
| NCT06221969A Research Study to See How Much CagriSema Lowers Blood Sugar and Body Weight Compared to Tirzepatide in People With Type 2 Diabetes Treated With Metformin With or Without an SGLT2 Inhibitor | CagriSema / cagrilintide, Semaglutide, Tirzepatide Obesity / overweight, Type 2 diabetes | BMI ≥30 | Ph 3 | Completed | 196 | Mar 2026 | — | |
| COMMIT-UCMirikizumab Administered at the Same Time as Tirzepatide in Adult Participants With Moderately to Severely Active Ulcerative Colitis and Obesity or Overweight: Phase 3b Study | Tirzepatide Gastrointestinal (gastroparesis / short bowel / pancreatitis), Obesity / overweight | — | Ph 3 | Recruiting | 190 | Apr 2028 | — | |
| COMMIT-CDMirikizumab and Tirzepatide Administered in Adult Participants With Moderately to Severely Active Crohn's Disease and Obesity or Overweight | Tirzepatide Gastrointestinal (gastroparesis / short bowel / pancreatitis), Obesity / overweight | BMI ≥30 | Ph 3 | Recruiting | 187 | May 2028 | — | |
| REIMAGINE 5A Research Study to See How Much CagriSema Lowers Blood Sugar and Body Weight Compared to Tirzepatide in People With Type 2 Diabetes Treated With Metformin, SGLT2 Inhibitor or Both | CagriSema / cagrilintide, Semaglutide, Tirzepatide Obesity / overweight, Type 2 diabetes | BMI ≥30 | Ph 3 | Active, not recruiting | 163 | Jun 2026 | — | |
| SURPASS-T1D-1A Study of Tirzepatide (LY3298176) Compared With Placebo in Adults With Type 1 Diabetes and Obesity or Overweight | Tirzepatide Obesity / overweight, Type 1 diabetes | BMI ≥25 | Ph 3 | Active, not recruiting | 146 | Nov 2026 | — | |
| NCT04847557A Study of Tirzepatide (LY3298176) in Participants With Heart Failure With Preserved Ejection Fraction (HFpEF) and Obesity: The SUMMIT Trial | Tirzepatide Heart failure, Obesity / overweight | BMI ≥30 | Ph 3 | Completed | 146 | Jul 2024 | 7 | results |
| SURPASS-6A Study of Tirzepatide (LY3298176) Versus Insulin Lispro (U100) in Participants With Type 2 Diabetes Inadequately Controlled on Insulin Glargine (U100) With or Without Metformin | Tirzepatide Type 2 diabetes | BMI ≥23 | Ph 3 | Completed | 135 | Oct 2022 | 2 | results |
| SURPASS-2A Study of Tirzepatide (LY3298176) Versus Semaglutide Once Weekly as Add-on Therapy to Metformin in Participants With Type 2 Diabetes | GLP-1 / incretin class catch-all, Semaglutide, Tirzepatide Type 2 diabetes | BMI ≥25 | Ph 3 | Completed | 127 | Jan 2021 | 9 | results |
| SURPASS-3A Study of Tirzepatide (LY3298176) Versus Insulin Degludec in Participants With Type 2 Diabetes | Tirzepatide Type 2 diabetes | BMI ≥25 | Ph 3 | Completed | 122 | Dec 2020 | 9 | results |
| SURMOUNT-1A Study of Tirzepatide (LY3298176) in Participants With Obesity or Overweight | Tirzepatide Obesity / overweight, Prediabetes / glucose intolerance | BMI ≥30 | Ph 3 | Completed | 118 | Apr 2022 | 14 | results |
| SYNERGY-NASHA Study of Tirzepatide (LY3298176) in Participants With Nonalcoholic Steatohepatitis (NASH) | Tirzepatide MASH / NAFLD / liver fibrosis, Obesity / overweight | BMI ≥27 | Ph 2 | Completed | 112 | Dec 2023 | 1 | results |
| NCT06326047A Research Study Comparing How Well Different Doses of the Medicine NN0519-0130 Lower Blood Sugar in People With Type 2 Diabetes | NNC0519-0130, Tirzepatide Type 2 diabetes | HbA1c 7.5-10% | Ph 2 | Completed | 94 | Sep 2025 | — | |
| SURPASS-EARLYA Study of Tirzepatide Compared With Intensified Conventional Care in Adult Participants With Type 2 Diabetes | Tirzepatide Type 2 diabetes | HbA1c 7-9.5% | Ph 4 | Active, not recruiting | 90 | Oct 2025 | 1 | |
| TOGETHER-PsAIxekizumab Concomitantly Administered With Tirzepatide in Adults With Psoriatic Arthritis and Obesity or Overweight | Tirzepatide Obesity / overweight, Psoriasis / psoriatic arthritis | BMI ≥30 | Ph 3 | Completed | 86 | Nov 2025 | 1 | |
| SURPASS-T1D-2A Long-Term Study of Tirzepatide (LY3298176) in Adults With Type 1 Diabetes and Obesity or Overweight | Tirzepatide Obesity / overweight, Type 1 diabetes | BMI ≥25 | Ph 3 | Active, not recruiting | 79 | Nov 2026 | — | |
| SURMOUNT-2A Study of Tirzepatide (LY3298176) in Participants With Type 2 Diabetes Who Have Obesity or Are Overweight | Tirzepatide Obesity / overweight, Type 2 diabetes | BMI ≥27 | Ph 3 | Completed | 75 | Mar 2023 | 4 | results |
| NCT06439277A Study of Tirzepatide in Adolescents With Obesity and Weight-Related Comorbidities (SURMOUNT-ADOLESCENTS-2) | Tirzepatide Dyslipidemia, Hypertension, Obesity / overweight, Prediabetes / glucose intolerance | Age 12-17 | Ph 3 | Recruiting | 73 | Oct 2027 | — | |
| TOGETHER-PsOIxekizumab Concomitantly Administered With Tirzepatide in Adults With Moderate-to-Severe Plaque Psoriasis and Obesity or Overweight | Tirzepatide Obesity / overweight, Psoriasis / psoriatic arthritis | BMI ≥30 | Ph 3 | Active, not recruiting | 72 | Jan 2026 | 1 | |
| SURMOUNT-4A Study of Tirzepatide (LY3298176) in Participants With Obesity or Overweight for the Maintenance of Weight Loss | Tirzepatide Obesity / overweight | BMI ≥30 | Ph 3 | Completed | 70 | Apr 2023 | 8 | results |
| NCT06326060A Research Study Comparing How Well Different Doses of the Medicine NN0519-0130 Help People With Excess Body Weight Lose Weight | NNC0519-0130, Tirzepatide Obesity / overweight | BMI ≥27 | Ph 2 | Completed | 70 | Apr 2025 | — | |
| NCT04093752A Study of Tirzepatide (LY3298176) in Participants With Type 2 Diabetes on Metformin With or Without Sulfonylurea (SURPASS-AP-Combo) | Tirzepatide Type 2 diabetes | BMI ≥23 | Ph 3 | Completed | 67 | Nov 2021 | 2 | results |
| TRIUMPH-5A Study of Retatrutide (LY3437943) Compared to Tirzepatide (LY3298176) in Adults Who Have Obesity | Retatrutide, Tirzepatide Obesity / overweight | — | Ph 3 | Active, not recruiting | 65 | Dec 2026 | — | |
| SURMOUNT-3A Study of Tirzepatide (LY3298176) In Participants After A Lifestyle Weight Loss Program | Tirzepatide Obesity / overweight | BMI ≥30 | Ph 3 | Completed | 65 | Apr 2023 | 6 | results |
| NCT06897475A Study of LY3457263 Compared With Placebo in Participants With Type 2 Diabetes on a Stable Dose of Semaglutide or Tirzepatide | Semaglutide, Tirzepatide Obesity / overweight, Type 2 diabetes | BMI ≥27 | Ph 2 | Recruiting | 60 | Dec 2026 | — | |
| SURMOUNT-OSAObstructive Sleep Apnea Master Protocol GPIF: A Study of Tirzepatide (LY3298176) in Participants With Obstructive Sleep Apnea | Tirzepatide Obesity / overweight, Sleep apnea | BMI ≥30 | Ph 3 | Completed | 58 | Mar 2024 | 5 | results |
| NCT06864026A Study to Investigate Effectiveness of Tirzepatide Following Initiation of Ixekizumab in Participants With Active Psoriatic Arthritis and Overweight or Obesity in Clinical Practice (TOGETHER AMPLIFY-PsA) | Tirzepatide Obesity / overweight, Psoriasis / psoriatic arthritis | — | Ph 4 | Recruiting | 55 | Nov 2027 | — | |
| NCT06143956A Master Protocol Study (LY900038) of Multiple Intervention-Specific-Appendices (ISAs) in Adult Participants With Obesity or Overweight | Eloralintide, Macupatide, Mazdutide, Tirzepatide Obesity / overweight | — | Ph 2 | Recruiting | 53 | Sep 2027 | — | |
| SURPASS-1A Study of Tirzepatide (LY3298176) in Participants With Type 2 Diabetes Not Controlled With Diet and Exercise Alone | Tirzepatide Type 2 diabetes | BMI ≥23 | Ph 3 | Completed | 53 | Oct 2020 | 5 | results |
| NCT06603571A Study to Investigate Weight Management With LY3841136 and Tirzepatide (LY3298176), Alone or in Combination, in Adult Participants With Obesity or Overweight With Type 2 Diabetes | Eloralintide, Tirzepatide Obesity / overweight, Type 2 diabetes | BMI ≥27 | Ph 2 | Active, not recruiting | 52 | Jun 2026 | — | |
| SURPASS-PEDSA Study to Evaluate Tirzepatide (LY3298176) in Pediatric and Adolescent Participants With Type 2 Diabetes Mellitus Inadequately Controlled With Metformin or Basal Insulin or Both | Tirzepatide Obesity / overweight, Type 2 diabetes | HbA1c 6.5-11% | Ph 3 | Completed | 51 | Jul 2024 | 1 | results |
| NCT06901349A Study of Bimagrumab (LY3985863) and Tirzepatide (LY3298176), Alone or in Combination, in Participants With Obesity or Overweight With Type 2 Diabetes | Tirzepatide Obesity / overweight, Type 2 diabetes | BMI ≥27 | Ph 2 | Withdrawn | 50 | Jun 2025 | — | |
| NCT03131687A Study of Tirzepatide (LY3298176) in Participants With Type 2 Diabetes Mellitus | Dulaglutide, Tirzepatide Type 2 diabetes | BMI 23-50 | Ph 2 | Completed | 49 | Aug 2018 | 4 | results |
| SURPASS-5A Study of Tirzepatide (LY3298176) Versus Placebo in Participants With Type 2 Diabetes Inadequately Controlled on Insulin Glargine With or Without Metformin | Tirzepatide Type 2 diabetes | BMI ≥23 | Ph 3 | Completed | 48 | Dec 2020 | 6 | results |
| SURPASS J-monoA Study of Tirzepatide (LY3298176) Compared to Dulaglutide in Participants With Type 2 Diabetes | Dulaglutide, Tirzepatide Type 2 diabetes | BMI ≥23 | Ph 3 | Completed | 46 | Mar 2021 | 6 | results |
| NCT06131437A Research Study to See How Well CagriSema Compared to Tirzepatide Helps People With Obesity Lose Weight | CagriSema / cagrilintide, Semaglutide, Tirzepatide Obesity / overweight | BMI ≥30 | Ph 3 | Completed | 46 | Dec 2025 | — | |
| NCT06857942A Study to Investigate the Effectiveness of Tirzepatide (LY3298176) Following Initiation of Ixekizumab (LY2439821) in Participants With Moderate-to-Severe Plaque PsO and Obesity or Overweight in Clinical Practice (TOGETHER AMPLIFY-PsO) | Tirzepatide Obesity / overweight, Psoriasis / psoriatic arthritis | — | Ph 4 | Recruiting | 41 | May 2028 | — | |
| NCT06037252A Study of Investigational Tirzepatide (LY3298176) Doses in Participants With Type 2 Diabetes and Obesity | Tirzepatide Obesity / overweight, Type 2 diabetes | BMI ≥35 | Ph 2 | Active, not recruiting | 40 | Jan 2026 | — | |
| SURPASS-SWITCHA Study of Tirzepatide (LY3298176) in Adult Participants With Type 2 Diabetes Switching From Dulaglutide (SURPASS-SWITCH) | Dulaglutide, Tirzepatide Obesity / overweight, Type 2 diabetes | BMI ≥25 | Ph 4 | Completed | 38 | Jul 2024 | 2 | results |
| GYMINDAA Study to Assess Efficacy, Safety, Tolerability, Pharmacokinetics (PK) and Pharmacodynamics (PD) of RO7204239 in Combination With Tirzepatide in Participants With Obesity or Overweight With At Least One Weight-related Comorbidity | Tirzepatide Obesity / overweight | BMI ≥30 | Ph 2 | Active, not recruiting | 35 | Aug 2026 | — | |
| NCT03861039A Long-term Safety Study of Tirzepatide (LY3298176) in Participants With Type 2 Diabetes | Tirzepatide Type 2 diabetes | BMI ≥23 | Ph 3 | Completed | 34 | Jan 2021 | 2 | results |
| NCT06075667A Study of Tirzepatide (LY3298176) Once Weekly in Adolescent Participants Who Have Obesity or Overweight With Weight-Related Comorbidities | Tirzepatide Obesity / overweight | HbA1c ≤9% | Ph 3 | Active, not recruiting | 33 | May 2026 | — | |
| REMAIN-1Evaluation of the Safety and Efficacy of Revita® DMR on Body Weight Maintenance in Subjects With Obesity Who Have Achieved at Least 15% Weight Loss on Tirzepatide | Tirzepatide Obesity / overweight | BMI ≥30 | Not applicable | Active, not recruiting | 32 | Feb 2027 | — | |
| NCT05706506A Study of Tirzepatide (LY3298176) in Adults With Type 2 Diabetes Switching From a GLP-1 RA (SURPASS-SWITCH-2) | Tirzepatide Obesity / overweight, Type 2 diabetes | BMI ≥25 | Ph 4 | Completed | 32 | Oct 2023 | — | results |
| SURMOUNT-5A Study of Tirzepatide (LY3298176) in Participants With Obesity or Overweight With Weight Related Comorbidities | Semaglutide, Tirzepatide Obesity / overweight | BMI ≥30 | Ph 3 | Completed | 32 | Nov 2024 | 3 | results |
| NCT07247084A Study of Tirzepatide (LY3298176) Compared With Standard of Care in Adult Participants With Obesity and Without Diabetes (SURMOUNT-REAL UK) | Tirzepatide Obesity / overweight | BMI 30-34.9 | Ph 4 | Recruiting | 30 | Jul 2029 | — | |
| SURMOUNT-CNA Study of Tirzepatide (LY3298176) in Chinese Participants Without Type 2 Diabetes Who Have Obesity or Overweight (SURMOUNT-CN) | Tirzepatide Obesity / overweight | BMI ≥28 | Ph 3 | Completed | 29 | Dec 2022 | 1 | results |
| T-RAMA Study of Tirzepatide (LY3298176) in Participants With Type 2 Diabetes During Ramadan | Tirzepatide Obesity / overweight, Type 2 diabetes | BMI ≥25 | Ph 4 | Completed | 29 | Apr 2026 | — | |
| NCT05963022A Study of Tirzepatide (LY3298176) in Chinese Participants With Type 2 Diabetes (SURPASS-CN-MONO) | Tirzepatide Type 2 diabetes | BMI ≥23 | Ph 3 | Completed | 28 | Oct 2024 | — | results |
| TREASURE-CKDA Study of Tirzepatide (LY3298176) in Participants With Overweight or Obesity and Chronic Kidney Disease With or Without Type 2 Diabetes | Tirzepatide Chronic kidney disease, Obesity / overweight | BMI ≥27 | Ph 2 | Active, not recruiting | 27 | Sep 2026 | 2 | |
| SURPASS-CN-INSA Study of Tirzepatide (LY3298176) in Chinese Participants With Type 2 Diabetes | Tirzepatide Type 2 diabetes | BMI ≥23 | Ph 3 | Completed | 25 | Jul 2024 | 1 | results |
| FLAMESFibrosis Lessens After Metabolic Surgery | GLP-1 / incretin class catch-all, Liraglutide, Semaglutide, Tirzepatide Bariatric Surgery Candidate, MASH / NAFLD / liver fibrosis, Obesity / overweight | BMI 35-70 | Ph 4 | Recruiting | 22 | May 2029 | — | |
| NCT07438444A Study of Tirzepatide (LY3298176) in Adult Participants in India With Either Type 2 Diabetes Mellitus or Obesity | Tirzepatide Obesity / overweight, Type 2 diabetes | BMI ≥23 | Ph 4 | Recruiting | 21 | Oct 2027 | — | |
| NCT06737042Efficacy and Safety of GZR18 Every 2 Weeks Versus Tirzepatide and Placebo in Obese or Overweight Participants | GZR18, Tirzepatide Obesity / overweight | BMI ≥30 | Ph 2 | Not yet recruiting | 20 | Feb 2026 | — | |
| NCT06047548A Study of LY3298176 (Tirzepatide) For the Maintenance of Body Weight Reduction in Participants Who Have Obesity or Overweight With Weight-Related Comorbidities | Tirzepatide Obesity / overweight | BMI ≥30 | Ph 3 | Completed | 20 | Jan 2026 | 2 | |
| SURMOUNT-JA Study of Tirzepatide (LY3298176) in Participants With Obesity Disease | Tirzepatide Obesity / overweight | BMI ≥27 | Ph 3 | Completed | 18 | Jun 2023 | 3 | results |
| NCT06732245Safety and Efficacy of NA-931 and Tirzepatide in Adults Who Are Overweight or Obese | GLP-1 / incretin class catch-all, NA-931, Tirzepatide Obesity / overweight | BMI ≥30 | Ph 2 | Not yet recruiting | 17 | Aug 2027 | — | |
| NCT06373146A Study of Tirzepatide (LY3298176) Plus Mibavademab Compared With Tirzepatide Alone in Adult Participants With Obesity | Tirzepatide Obesity / overweight | BMI ≥30 | Ph 2 | Completed | 17 | Dec 2025 | — | |
| NCT07262762Spartina® (Tirzepatide) Effectiveness and Safety Evaluation | Tirzepatide Obesity / overweight | BMI ≥30 | — | Recruiting | 14 | Dec 2025 | — | |
| STRIDESEfficacy and Safety of Oral Azelaprag Plus Once Weekly Tirzepatide Compared with Tirzepatide Alone in Participants with Obesity Aged 55 Years and Over | Tirzepatide Obesity / overweight | BMI 30-40 | Ph 2 | Terminated | 14 | Feb 2025 | — | |
| NCT03311724A Study of Tirzepatide (LY3298176) in Participants With Type 2 Diabetes | Tirzepatide Type 2 diabetes | BMI 23-45 | Ph 2 | Completed | 13 | Apr 2018 | — | results |
| NCT06643728A Study to Investigate Weight Management With Bimagrumab (LY3985863) and Tirzepatide (LY3298176), Alone or in Combination, in Adults With Obesity or Overweight | Tirzepatide Obesity / overweight | — | Ph 2 | Active, not recruiting | 12 | Jan 2026 | — | |
| TIRZ-DOSE-NLReal-world Effectiveness and Dosing Patterns of Tirzepatide in People With Obesity | Tirzepatide Obesity / overweight | BMI ≥30 | — | Not yet recruiting | 10 | Jul 2026 | 3 | |
| TABEvaluation of Tirzepatide as an Adjunct to Buprenorphine for the Treatment of Opioid Use Disorder | Tirzepatide Alcohol / substance use | — | Ph 2 | Recruiting | 9 | Sep 2027 | — | |
| NCT06937203A First-In-Human Study of ARO-ALK7 in Adults With Obesity With and Without Type 2 Diabetes Mellitus | Tirzepatide Obesity / overweight, Type 2 diabetes | BMI 30-50 | Ph 1/2 | Recruiting | 8 | Oct 2026 | — | |
| FITWISETirzepatide for Weight Loss Intervention in Early-Stage Hormone Receptor Positive/HER2 Negative Breast Cancer | Tirzepatide Obesity / overweight, Oncology | — | Ph 2 | Recruiting | 7 | Sep 2027 | — | |
| NCT06751589A Study of a Weight Loss Intervention in People With Endometrial Cancer | Semaglutide, Tirzepatide Obesity / overweight, Oncology | BMI ≥30 | Early Ph 1 | Recruiting | 7 | Dec 2027 | — | |
| EMBRAZEEfficacy and Safety of Apitegromab for the Treatment of Adults Who Are Overweight or Obese | Tirzepatide Obesity / overweight | — | Ph 2 | Completed | 7 | Mar 2025 | — | |
| DehydraTECHComparison of the Safety, Efficacy and Pharmacokinetics of DehydraTECH -CBD and DehydraTECH-GLP1 Agonists Alone or in Combination, in Overweight or Obese, Pre- and Type 2 Diabetic Participants | Semaglutide, Tirzepatide Obesity / overweight | BMI 0-40 | Ph 1 | Completed | 7 | Jul 2025 | — | |
| NCT05822544Phase 1/1b Study of TLC-6740 in Healthy Subjects and Subjects With Obesity, With or Without Diabetes | Tirzepatide Healthy volunteers, Obesity / overweight | BMI 19-35 | Ph 1 | Recruiting | 4 | Feb 2026 | — | |
| STOP KNEE-OASubcutaneous Tirzepatide Once-weekly in Patients With Obesity and Knee Osteoarthritis (STOP KNEE-OA) | Tirzepatide Obesity / overweight, Osteoarthritis | — | Ph 4 | Recruiting | 4 | May 2027 | 1 | |
| BMT-801A Phase 2 Study Evaluating the Co-Administration of Bremelanotide With Tirzepatide for the Treatment of Obesity | Tirzepatide Obesity / overweight | BMI 30-45 | Ph 2 | Active, not recruiting | 4 | Feb 2025 | — | |
| GLP1-TASTEChanges in Taste and Eating Habits Associated With GLP-1 Agonists in Weight Loss Patients | GLP-1 / incretin class catch-all, Semaglutide, Tirzepatide Obesity / overweight | — | — | Recruiting | 4 | Jan 2027 | 1 | |
| TZPA Clinical Trial Using Tirzepatide to Help Adults With Type 1 Diabetes Automatically Control Their Blood Sugar | Tirzepatide Obesity / overweight, Type 1 diabetes | BMI ≥27 | Ph 2/3 | Recruiting | 4 | Jan 2028 | 22 | |
| COMBAT-PsACombination of Biologic and Anti-obesity Therapies in Psoriatic Arthritis | GLP-1 / incretin class catch-all, Tirzepatide Obesity / overweight, Psoriasis / psoriatic arthritis | BMI ≥27 | Not applicable | Recruiting | 4 | Feb 2028 | 14 | |
| NCT03482024A Study of Tirzepatide (LY3298176) in Participants With Impaired Kidney Function | Tirzepatide Healthy volunteers, Renal impairment | BMI 19-40 | Ph 1 | Completed | 4 | Aug 2019 | 1 | results |
| NCT06400615Study That Tests AD109 in Patients Taking GLP-1 Drugs | Liraglutide, Semaglutide, Tirzepatide Obesity / overweight, Sleep apnea | BMI 27-43 | Ph 2 | Completed | 4 | Dec 2024 | — | |
| NCT07602699Multi-Site Trial of Tirzepatide for Smoking Cessation | Tirzepatide Alcohol / substance use, Obesity / overweight | BMI ≥25 | Ph 2 | Recruiting | 4 | Mar 2028 | — | |
| NCT06431308Nutritional Therapy to Incretin-based Anti-obesity Medications in the Management of Gastrointestinal Adverse Events | Semaglutide, Tirzepatide Obesity / overweight | BMI ≥30 | Not applicable | Recruiting | 3 | Feb 2026 | — | |
| IDEAL-CORThe Effects of Tirzepatide in People With Overweight/Obesity and Coronary Artery Disease | Tirzepatide Cardiovascular disease, Obesity / overweight | BMI ≥27 | Ph 4 | Recruiting | 3 | Mar 2027 | 39 | |
| NCT06700538A First-In-Human Study of ARO-INHBE in Adults With Obesity With and Without Type 2 Diabetes Mellitus | Tirzepatide Obesity / overweight, Type 2 diabetes | BMI 30-50 | Ph 1/2 | Recruiting | 3 | Sep 2027 | — | |
| NCT06901245Tirzepatide in PWS, HO and GNSO | GLP-1 / incretin class catch-all, Tirzepatide Hypothalamic / syndromic obesity, Obesity / overweight | — | Ph 4 | Recruiting | 3 | Jun 2026 | — | |
| NCT07099742Effectiveness and Safety of Tirzepatide Among Participants With Obesity With or Without Type 2 Diabetes Mellitus (T2DM) | Tirzepatide Obesity / overweight | BMI ≥25 | — | Not yet recruiting | 3 | Apr 2026 | 4 | |
| NCT07349641A Study of Weight Loss Intervention With Tirzepatide and Progestin Intrauterine Device to Treat Endometrial Hyperplasia and Grade 1 Endometrial Cancer | Tirzepatide Obesity / overweight, Oncology | BMI ≥27 | Ph 2 | Not yet recruiting | 3 | Dec 2028 | — | |
| NCT03940742A Study of Tirzepatide in Participants With Impaired Liver Function | Tirzepatide Healthy volunteers, Hepatic impairment, Type 2 diabetes | BMI 19-40 | Ph 1 | Completed | 3 | Sep 2020 | 1 | results |
| NCT04311411A Study of Tirzepatide in Overweight and Very Overweight Participants | Liraglutide, Tirzepatide Obesity / overweight | BMI 27-50 | Ph 1 | Completed | 3 | Dec 2022 | 1 | results |
| NCT05696847A Study of Tirzepatide (LY3298176) in Pediatric Participants With Obesity | Tirzepatide Obesity / overweight | Age 6-11 | Ph 1 | Completed | 3 | Jan 2025 | — | results |
| NCT05810597A Research Study Looking at Similarity Between Tirzepatide Versions for Different Injection Devices | Tirzepatide Healthy volunteers | BMI 18.5-30 | Ph 1 | Completed | 3 | Jul 2023 | — | results |
| NCT06297616A Study of LY3841136 in Japanese Participants With Obesity or Overweight | Eloralintide, Tirzepatide Obesity / overweight | BMI 27-40 | Ph 1 | Completed | 3 | Nov 2025 | — | |
| NCT06345066A Study of LY3841136 in Overweight and Obese Participants | Eloralintide, Tirzepatide Obesity / overweight | BMI 27-45 | Ph 1 | Completed | 3 | Sep 2025 | — | |
| NCT06916065A Study of Eloralintide (LY3841136) and Eloralintide With Tirzepatide in Participants With Overweight or Obesity | Eloralintide, Tirzepatide Obesity / overweight | BMI 27-40 | Ph 1 | Completed | 3 | Jan 2026 | — | |
| AID-JUNCTGIP/GLP-1RA as Adjunctive to Automated Insulin Delivery in Adults With Type 1 Diabetes | Tirzepatide Type 1 diabetes | BMI ≥23 | Ph 3 | Recruiting | 3 | Jun 2026 | — | |
| NCT06976853Moving Beyond Inflammation as a Therapeutic Target for Crohn's Disease | Tirzepatide Gastrointestinal (gastroparesis / short bowel / pancreatitis) | — | Ph 2 | Recruiting | 3 | May 2028 | — | |
| NCT05756764Anti-obesity Pharmacotherapy and Inflammation | GLP-1 / incretin class catch-all, Liraglutide, Semaglutide, Tirzepatide Obesity / overweight | BMI ≥30 | — | Active, not recruiting | 2 | Jan 2026 | — | |
| NCT06246799Comparative Effectiveness of Two Initial Combination Therapies in Patients With Recent Onset Diabetes | Tirzepatide Type 2 diabetes | HbA1c ≥6.5% | Ph 3 | Recruiting | 2 | Apr 2029 | — | |
| STREAMStudy of Tirzepatide for Recovery and Alcohol Use Management | Tirzepatide Alcohol / substance use | — | Ph 2 | Recruiting | 2 | May 2026 | — | |
| MAINTAINMAINTAIN (Mucosal AblatIoN Therapy After INcretins) | Semaglutide, Tirzepatide Obesity / overweight | BMI ≥30 | Not applicable | Recruiting | 2 | Jun 2026 | 3 | |
| DUALPSYCHIATRYEffects of Tirzepatide on Alcohol Intake in Patients Diagnosed With Schizophrenia and Alcohol Use Disorder | Tirzepatide Alcohol / substance use, Psychiatric (schizophrenia / bipolar / depression) | — | Ph 2 | Recruiting | 2 | Aug 2028 | — | |
| PERIODSA Clincial Study Testing Tirzepatide on Reproductive Function and Metabolic Health in Women With PCOS Who Are Overweight or Obese | Tirzepatide Obesity / overweight, PCOS | BMI ≥27 | Ph 4 | Recruiting | 2 | Dec 2028 | — | |
| NCT07444073Assessing Biological Aging in a Real-World Medical Weight Loss Program Using the LinAge2 Clinical Clock | GLP-1 / incretin class catch-all, Semaglutide, Tirzepatide Obesity / overweight | BMI ≥27.5 | — | Not yet recruiting | 2 | Dec 2026 | 1 | |
| NCT02759107A Study of Tirzepatide (LY3298176) in Healthy Participants and Participants With Type 2 Diabetes (T2DM) | Dulaglutide, Tirzepatide Healthy volunteers, Type 2 diabetes | BMI ≥18.5 | Ph 1 | Completed | 2 | Jun 2017 | 1 | results |
| NCT03322631A Study of Tirzepatide (LY3298176) in Japanese Participants With Type 2 Diabetes | Tirzepatide Type 2 diabetes | BMI 20-35 | Ph 1 | Completed | 2 | May 2018 | — | results |
| NCT03951753A Study of Tirzepatide in Participants With Type 2 Diabetes Mellitus (T2DM) | Semaglutide, Tirzepatide Obesity / overweight, Type 2 diabetes | BMI 25-45 | Ph 1 | Completed | 2 | Apr 2021 | 2 | results |
| NCT04235959A Study of Tirzepatide in Chinese Participants With Type 2 Diabetes Mellitus | Tirzepatide Type 2 diabetes | — | Ph 1 | Completed | 2 | Aug 2021 | 1 | results |
| NCT06485089Effects of Tirzepatide on Blood, Imaging and Breast Tissue Biomarkers | Tirzepatide Obesity / overweight, Oncology | BMI 30-45 | — | Completed | 2 | Mar 2026 | — | |
| NCT06533527Holding vs. Continuing Incretin-based Therapies Before Upper Endoscopy | Dulaglutide, Liraglutide, Semaglutide, Tirzepatide Perioperative / gastric aspiration risk | — | Ph 4 | Completed | 2 | May 2025 | 4 | results |
| NCT06657209Normal-weight Diabetes: Adipocyte-directed Therapy With Pioglitazone or Tirzepatide | Tirzepatide Healthy volunteers, Type 2 diabetes | BMI 19-24.9 | Ph 4 | Recruiting | 2 | Dec 2027 | — | |
| OPTIMIZE-GENGenetic, Microbiological and Behavioral Factors in Obesity | Tirzepatide Obesity / overweight | BMI ≥27 | — | Recruiting | 2 | May 2027 | — | |
| T-PLAQUEEffect of Tirzepatide on Progression of Coronary Atherosclerosis Using MDCT | Tirzepatide Cardiovascular disease, Obesity / overweight, Type 2 diabetes | BMI ≥25 | Ph 4 | Recruiting | 1 | Dec 2025 | — | |
| NCT05912621Tirzepatide: Reversal of Lipotoxicity and Adipose Tissue Dysfunction in Humans With Overweight/Obesity | Tirzepatide Obesity / overweight | BMI 27-39.9 | Ph 2 | Recruiting | 1 | Jun 2028 | — | |
| NCT05933499Effect of Tirzepatide and Bimagrumab on Body Composition, Insulin Sensitivity, and Bone in Adults With Obesity | Tirzepatide Obesity / overweight | BMI ≥30 | Ph 2 | Recruiting | 1 | Dec 2028 | — | |
| GRABS-0GLP-1 Receptor Agonists Post-Bariatric Surgery (GRABS) Pilot Trial | Tirzepatide Bariatric Surgery, Obesity / overweight | BMI ≥30 | Ph 2/3 | By invitation | 1 | Jan 2027 | — | |
| NCT06467604CRAVE Study: Comparing Craving Responses and Diet Quality of GLP1 Receptor Agonist Users | GLP-1 / incretin class catch-all, Semaglutide, Tirzepatide Obesity / overweight | BMI ≥30 | — | Active, not recruiting | 1 | Mar 2027 | — | |
| TRIM-EBCTirzepatide Weight Loss for MRD+ Early Breast Cancer | Tirzepatide Obesity / overweight, Oncology | BMI ≥27 | Ph 2 | Recruiting | 1 | Aug 2029 | — | |
| NCT06582875Glucagon-Like Peptide-1 Receptor Agonist in ADPKD | Tirzepatide Chronic kidney disease, Obesity / overweight | BMI ≥27 | Ph 2 | Recruiting | 1 | Jun 2029 | 1 | |
| NCT067215072024 Tirzepatide-Bariatric Surgery | Tirzepatide Bariatric Surgery, Bariatric Surgery Candidate, Obesity / overweight | BMI ≥40 | Ph 4 | Recruiting | 1 | Dec 2026 | 1 | |
| NCT06734273Randomized Control Trial of Sleeve Gastrectomy With Tirzepatide in Maximizing Weight Loss | Tirzepatide Bariatric Surgery, Obesity / overweight | BMI ≥35 | Early Ph 1 | Recruiting | 1 | Sep 2027 | — | |
| NCT06745128Tirzepatide for Obesity and Meth Use Disorder | Tirzepatide Alcohol / substance use, Obesity / overweight | — | Ph 2 | Active, not recruiting | 1 | Mar 2026 | 8 | |
| NCT06759701Pre-Surgical Tirzepatide-Assisted Weight Loss in Overweight and Obese Men With Intermediate Risk Prostate Cancer: A Pilot Feasibility Study | Tirzepatide Obesity / overweight, Oncology | BMI ≥27 | Early Ph 1 | Recruiting | 1 | Dec 2026 | — | |
| NCT06774079Glucagon-like Peptide-1 Receptor Agonist (GLP-1 RA) and Diet in Inflammatory Bowel Disease (IBD) Patients | Tirzepatide Gastrointestinal (gastroparesis / short bowel / pancreatitis) | BMI ≥27 | Ph 4 | Recruiting | 1 | Mar 2027 | — | |
| NCT06790160Study of Patients Being Treated With Anti-obesity Medication | Semaglutide, Tirzepatide Obesity / overweight | BMI ≥30 | — | Recruiting | 1 | Dec 2027 | — | |
| NCT06801015Effects of Long-Acting GLP-1 (Glucagon-like Peptide-1) or Dual Incretin (GLP-1 and GIP [Glucose-dependent Insulinotropic Peptide]) Modulation on Gastric Motor Functions | Semaglutide, Tirzepatide Obesity / overweight, Prediabetes / glucose intolerance, Type 2 diabetes | BMI ≥30 | Ph 4 | Active, not recruiting | 1 | Jan 2028 | — | |
| TIRO-AFTIRzepatide for the Treatment of Obesity in Patients With Atrial Fibrillation | Tirzepatide Atrial fibrillation, Obesity / overweight | BMI 27-60 | Ph 2 | Recruiting | 1 | Dec 2026 | — | |
| NCT06803888Bariatric Surgery vs. Semaglutide vs. Tirzepatide | GLP-1 / incretin class catch-all, Semaglutide, Tirzepatide Bariatric Surgery Candidate, Obesity / overweight | BMI 35-65 | Ph 4 | Active, not recruiting | 1 | Jul 2027 | — | |
| NCT06811324Effects of Tirzepatide on Muscle and Vascular Health in Obese Older Adults | Tirzepatide Obesity / overweight | BMI ≥30 | Ph 2 | Recruiting | 1 | Apr 2027 | 13 | |
| LIBERATEEfficacy and Safety of Tirzepatide Versus Placebo or Lisdexamfetamine Dimesylate for Binge-Eating Disorder | Tirzepatide Feeding And Eating Disorders, Obesity / overweight | BMI ≥30 | Ph 2 | Recruiting | 1 | Dec 2027 | — | |
| GLOWGLP-1s to Enhance Lasting Optimal Weight | Tirzepatide Obesity / overweight | BMI 30-37 | Ph 4 | Active, not recruiting | 1 | Sep 2026 | — | |
| LEAN-PREPLEAN Mass Preservation With Resistance Exercise and Protein During Semaglutide/Tirzepatide Therapy | Semaglutide, Tirzepatide Obesity / overweight | — | Not applicable | Recruiting | 1 | Aug 2029 | 7 | |
| TABFATEffect of Tirzepatide on Brown Adipose Tissue in Obesity | Tirzepatide Obesity / overweight | Female | Ph 2 | Active, not recruiting | 1 | Nov 2025 | 1 | |
| NCT06911203A Study of BGM0504 in Participants With Obesity | BGM0504, Tirzepatide Obesity / overweight | — | Ph 2 | Recruiting | 1 | Jan 2026 | — | |
| NCT06918405Efficacy and Safety of Tirzepatide for Weight Management | Tirzepatide Obesity / overweight, Type 2 diabetes | HbA1c ≤10% | Ph 3 | Active, not recruiting | 1 | Jun 2026 | — | |
| NCT06934642Effect of Tirzepatide on Markers of MASLD in Patients With Obesity | Tirzepatide MASH / NAFLD / liver fibrosis, Obesity / overweight | BMI ≥25 | Early Ph 1 | Recruiting | 1 | Aug 2026 | — | |
| NCT06935838Effects of Tirzepatide on Weight Loss and Chronic Inflammation in People With HIV | Tirzepatide HIV, Obesity / overweight | BMI ≥27 | Ph 2 | Recruiting | 1 | Jul 2026 | 13 | |
| NCT06980623Comparative Effectiveness of Tirzepatide vs Semaglutide in Participants With Type 2 Diabetes and Heart Failure With Preserved Ejection Fraction | Semaglutide, Tirzepatide Heart failure, Type 2 diabetes | — | — | Active, not recruiting | 1 | Nov 2025 | — | |
| NCT06994338Tirzepatide for Alcohol Use Disorder | Tirzepatide Alcohol / substance use, Obesity / overweight | BMI ≥27 | Ph 2 | Recruiting | 1 | Aug 2026 | — | |
| NCT07000955Tolerance and Pharmacokinetic/Pharmacokinetic Study of IBI362 15mg in Patients With Moderate to Severe Obesity | Mazdutide, Tirzepatide Obesity / overweight | BMI ≥32.5 | Ph 1/2 | Active, not recruiting | 1 | Sep 2026 | — | |
| METSAFEMetabolic Surgery for Atrial Fibrillation Elimination | Dulaglutide, GLP-1 / incretin class catch-all, Liraglutide, Semaglutide, Tirzepatide Atrial fibrillation, Bariatric Surgery Candidate, Obesity / overweight | BMI 35-65 | Ph 4 | Not yet recruiting | 1 | Dec 2029 | — | |
| SEM-TIR24-h Energy Expenditure and Anti-obesity Medication | Semaglutide, Tirzepatide Obesity / overweight | BMI ≥30 | — | By invitation | 1 | Jun 2026 | — | |
| BETTER-GLP1Behavioral Therapy and GLP-1 Analogue Effects on Binge Eating, Weight, and Coping in Obesity | GLP-1 / incretin class catch-all, Liraglutide, Semaglutide, Tirzepatide Feeding And Eating Disorders, Obesity / overweight | BMI ≥40 | — | Recruiting | 1 | Nov 2027 | — | |
| NCT07046819Tirzepatide in MetALD | Tirzepatide Alcohol / substance use, MASH / NAFLD / liver fibrosis, Obesity / overweight | BMI 25-40 | Ph 2 | Recruiting | 1 | Jul 2026 | 1 | |
| NCT07057310Aging Well: Targeting Obesity With GLP-1 Agonists to Enhance Physical and Vascular Health in Postmenopausal Women | Semaglutide, Tirzepatide Obesity / overweight, Reproductive / infertility | BMI ≥30 | Ph 4 | By invitation | 1 | Dec 2026 | — | |
| OPTIMALOptimizing Portal Hypertension With TIPS and Interval Metabolic Surgery for Advanced Liver Disease | GLP-1 / incretin class catch-all, Semaglutide, Tirzepatide Bariatric Surgery Candidate, Hepatic impairment, Obesity / overweight | BMI 35-70 | Ph 4 | Recruiting | 1 | Feb 2029 | — | |
| NCT07065552Tirzepatide in Obesity-Driven Endometrial Cancer | Tirzepatide Obesity / overweight, Oncology | BMI ≥30 | Early Ph 1 | Recruiting | 1 | Jul 2028 | — | |
| NCT07078838Tirzepatide in Women With Obesity and Endometrial Intra-epithelial Neoplasia or Grade 1 Endometrial Cancer | Tirzepatide Obesity / overweight, Oncology | BMI ≥30 | Ph 2 | Not yet recruiting | 1 | Mar 2029 | — | |
| TILT-2024Tirzepatide for Partial Lipodystrophy Treatment: A New Horizon in 2024 | Tirzepatide Diabetes (other / unspecified), Dyslipidemia | HbA1c ≥7% | Ph 2 | Recruiting | 1 | Sep 2029 | — | |
| TiLi-BONETirzepatide vs Liraglutide in Bone | Liraglutide, Tirzepatide Obesity / overweight | BMI ≥40 | — | Recruiting | 1 | Dec 2026 | 36 | |
| PROSPECTPathways, Risk Factors, and mOleculeS to Prevent Early-onset Colorectal Tumors | Tirzepatide Obesity / overweight, Oncology | BMI 27-40 | Ph 1 | Recruiting | 1 | Mar 2027 | — | |
| NCT07096908Tirzepatide Use in People With Obesity and Type 1 Diabetes | Tirzepatide Obesity / overweight, Type 1 diabetes | BMI ≥27 | Ph 4 | Recruiting | 1 | Feb 2028 | 1 | |
| REFORMComparison of Body Composition Changes With Weight Loss Interventions | GLP-1 / incretin class catch-all, Semaglutide, Tirzepatide Bariatric Surgery, Obesity / overweight | BMI 35-60 | — | Recruiting | 1 | Sep 2026 | — | |
| LOCITTThe Long COVID Treatment Trial | Tirzepatide COVID / long COVID | — | Ph 2 | Active, not recruiting | 1 | Dec 2026 | — | |
| GRAMSGLP-1R Actions on Muscle and the Skeleton | Tirzepatide Obesity / overweight | — | Ph 4 | Recruiting | 1 | Feb 2027 | 4 | |
| TirzepatideEfficacy and Safety of Tirzepatide (Spartina) in Chronic Kidney Failure | Tirzepatide Chronic kidney disease, Diabetes (other / unspecified), Obesity / overweight | BMI ≥27 | Not applicable | Not yet recruiting | 1 | Apr 2026 | — | |
| DASH-CKMHUsing Secondary Data to Evaluate Sex-based Heterogeneity of GLP-1 Agonists and SGLT2 Inhibitors on Cardiovascular-Kidney-Metabolic Health (CKMH) Outcomes in Real-world Settings (DASH-CKMH) | Albiglutide, Dulaglutide, Exenatide, Liraglutide, Lixisenatide, Semaglutide, Tirzepatide Metabolic syndrome | — | — | Active, not recruiting | 1 | Jun 2029 | — | |
| TIIHTTirzepatide in Idiopathic Intracranial Hypertension Trial | Tirzepatide Obesity / overweight, Pseudotumor Cerebri | BMI ≥30 | Ph 4 | Not yet recruiting | 1 | Feb 2027 | 5 | |
| NCT07202247Metabolic Interventions (Time-Restricted Eating, GLP1 Receptor Agonist, and Heart Healthy Diet) to Improve Cardiometabolic Health in Prostate Cancer Patients During Androgen Deprivation Therapy, IMPACT-ADT Trial | GLP-1 / incretin class catch-all, Semaglutide, Tirzepatide Obesity / overweight, Oncology | BMI ≥30 | Ph 2 | Recruiting | 1 | Apr 2028 | — | |
| PROBIO-GLP1Probiotic Intervention for Digestive Health in Obese Patients Initiating GLP-RA Treatment | GLP-1 / incretin class catch-all, Semaglutide, Tirzepatide Obesity / overweight | BMI ≥30 | Not applicable | Not yet recruiting | 1 | Apr 2027 | — | |
| NCT07218445The Effect of Tirzepatide on Menopausal Vasomotor Symptoms and Biological Aging in Post-menopausal Women With Obesity | Tirzepatide Obesity / overweight, Reproductive / infertility | BMI ≥30 | Ph 4 | Recruiting | 1 | Sep 2027 | — | |
| TEXPEFTailored Exercise Training Study Among Adults With HFpEF | Semaglutide, Tirzepatide Heart failure, Obesity / overweight | BMI ≥28 | Ph 2/3 | Recruiting | 1 | Dec 2026 | — | |
| NCT07228741Resistance Exercise and Incretin Mimetic for Cardiometabolic Health in Survivors of ALL With Obesity | Tirzepatide Obesity / overweight, Oncology | BMI ≥30 | Ph 2 | Recruiting | 1 | Nov 2027 | — | |
| NCT07245771Phase 1/2a Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Effect on Body Weight of RN3161 as Monotherapy and in Combination With Tirzepatide in Adults With Overweight and Obesity | Tirzepatide Healthy volunteers, Obesity / overweight | — | Ph 1/2 | Recruiting | 1 | Feb 2027 | — | |
| NCT07257484Tirzepatide's Role in Postmenopausal HR+ Breast Cancer Survivors | Tirzepatide Obesity / overweight, Oncology | BMI ≥30 | Ph 4 | Not yet recruiting | 1 | Oct 2027 | — | |
| NCT07292519Tirzepatide Combined With Cognitive-Behavioural Therapy (CBT) for Adults With Alcohol Use Disorder (AUD) and Overweight/Obesity (OOB) | Tirzepatide Alcohol / substance use, Obesity / overweight | BMI ≥27 | Ph 2 | Not yet recruiting | 1 | May 2027 | — | |
| NCT07293325Semaglutide and Tirzepatide for Genetic Aging Delay in Adults With Obesity | GLP-1 / incretin class catch-all, Semaglutide, Tirzepatide Obesity / overweight | BMI ≥30 | Not applicable | Recruiting | 1 | Apr 2027 | — | |
| EXER-MEDThe Effect of Exercise and Tirzepatide on Weight and Health Outcomes (EXER-MED) | Tirzepatide Obesity / overweight | — | Ph 3 | Not yet recruiting | 1 | Dec 2026 | — | |
| NCT07299084A Study to Evaluate the Effect of Fasting Duration and Tirzepatide Withholding on the Amount of Food and Fluid in the Stomach in Participants With Type 2 Diabetes Mellitus and Participants With Overweight or Obesity Without Type 2 Diabetes Mellitus | Tirzepatide Obesity / overweight, Type 2 diabetes | — | Ph 1 | Active, not recruiting | 1 | Nov 2026 | — | |
| ICDDTKZ26Improving Cardiovascular Disease Diagnosis and Treatment in Kazakhstan Using Metabolic Correction With GLP-1 Drugs | Tirzepatide Heart failure, Obesity / overweight, Type 2 diabetes | BMI ≥25 | Not applicable | Active, not recruiting | 1 | Jul 2025 | — | |
| ADIPO-CKDClinical, Morphometric and Biochemical Effects on Adiposopathy Associated With the Use of GLP-1RA in CKD | Dulaglutide, Exenatide, GLP-1 / incretin class catch-all, Liraglutide, Semaglutide, Tirzepatide Chronic kidney disease, Obesity / overweight, Type 2 diabetes | — | — | Recruiting | 1 | Jul 2027 | 15 | |
| NCT07319975Effect of Semaglutide and Tirzepatide Combined With Exercise in Obesity | Semaglutide, Tirzepatide Obesity / overweight | BMI 30-40 | Not applicable | Not yet recruiting | 1 | Oct 2026 | — | |
| SOLUTION-PilotA Trial Within Cohort Feasibility Study Design Comparing Standard of Care Versus Weight Loss (Achieved Through Tirzepatide) for Obesity-related Hypertension in Young Adults | Tirzepatide Hypertension, Obesity / overweight | BMI ≥27 | Not applicable | Recruiting | 1 | Jan 2027 | — | |
| TIRMOTirzepatide and Muscle Outcomes in Obesity | Tirzepatide Obesity / overweight | Female | Not applicable | Recruiting | 1 | Dec 2026 | — | |
| TREAT-AFTirzepatide to Reduce rEcurrence And Burden After Ablation of Atrial Fibrillation | Tirzepatide Atrial fibrillation, Obesity / overweight | BMI ≥27 | Not applicable | Not yet recruiting | 1 | Dec 2027 | — | |
| CLIN-GLP1Clinical and Neurobehavioral Changes With Weight Loss Drug Discontinuation and Reinitiation | Tirzepatide Obesity / overweight | — | Not applicable | Not yet recruiting | 1 | Feb 2028 | 30 | |
| INTERCEPTINcreTin-based thERapies for Cardiovascular Event PrevenTion in Patients With and Without ASCVD (INTERCEPT-ASCVD) | Dulaglutide, Semaglutide, Tirzepatide Cardiovascular disease, Obesity / overweight, Type 2 diabetes | BMI ≥25 | — | Active, not recruiting | 1 | May 2026 | — | |
| NCT07423247Tirzepatide (Spartina) in Obese Kidney Transplant Recipients | Tirzepatide Obesity / overweight, Renal impairment | BMI ≥27 | Ph 4 | Recruiting | 1 | Jul 2026 | — | |
| FLEXFunction and Lean Mass Preservation With Resistance Exercise During a GLP-1RA Treatment | Tirzepatide Obesity / overweight | BMI 30-35 | Not applicable | Recruiting | 1 | Dec 2027 | 5 | |
| NCT07463846A Study to Evaluate ALN-2232 in Participants With Obesity | Tirzepatide Obesity / overweight | BMI 30-40 | Ph 1/2 | Recruiting | 1 | Apr 2027 | — | |
| SURMOUNT-1Efficacy and Safety of Tirzepatide Once Weekly Versus Placebo in Participants Who Are Either Obese or Overweight With Weight-Related Comorbidities (SURMOUNT-1) | Tirzepatide Obesity / overweight | BMI ≥30 | Ph 3 | Recruiting | 1 | Feb 2027 | — | |
| DECODEDECODE - Haemodynamic Effects Of Semaglutide and Tirzepatide - a Series of Pilot Studies | GLP-1 / incretin class catch-all, Semaglutide, Tirzepatide Healthy volunteers, Hypertension, Obesity / overweight | BMI 18.5-24.9 | Ph 4 | Not yet recruiting | 1 | Apr 2027 | — | |
| NCT07492563Safety and Effectiveness of Tirzepatide in Patients With Obesity at Hospital de Clínicas, Paraguay | Tirzepatide Obesity / overweight | BMI ≥27 | — | Not yet recruiting | 1 | Oct 2026 | — | |
| NCT07521631Efficacy and Safety of HDM1005 Compared to Tirzepatide in Obese Adults Without Diabetes | HDM1005, Tirzepatide Obesity / overweight | BMI ≥28 | Ph 2 | Recruiting | 1 | Feb 2027 | — | |
| NCT07555730AI-assisted Multi-domain Lifestyle Versus Tirzepatide for Weight Loss Maintenance in Adults With Type 2 Diabetes (AIM-MAINTAIN) | Tirzepatide Obesity / overweight, Type 2 diabetes | BMI ≥27 | Ph 4 | Not yet recruiting | 1 | Sep 2028 | — | |
| CARTIZCARTIZ Registry: Cartilage, Arthropathy and Imaging Under Tirzepatide in Zone-stratified Cohorts - A Four-Institute Mexican Observational Registry | GLP-1 / incretin class catch-all, Tirzepatide Osteoarthritis, Psoriasis / psoriatic arthritis | — | — | Not yet recruiting | 1 | Nov 2027 | 13 | |
| NCT07573163Tirzepatide Following Adrenalectomy in Mild Autonomous Cortisol Secretion | Tirzepatide Hypertension, Obesity / overweight | BMI ≥27 | Ph 2 | Not yet recruiting | 1 | Jul 2028 | 17 | |
| REAL-TIRZEPYEfficacy, Safety, and Tolerability of Tirzepatide in Real-World Conditions in Paraguay. | Tirzepatide Obesity / overweight, Type 2 diabetes | BMI ≥30 | Ph 4 | Recruiting | 1 | Aug 2027 | — | |
| FLOURISHGLP-1 Medication & Behavioral Health Programs on Weight & Metabolic Outcomes: FLOURISH and THRIVE Prospective Cohort Study | Semaglutide, Tirzepatide Obesity / overweight | — | — | Not yet recruiting | 1 | May 2029 | — | |
| COMPARE-ATComparative Observation of Metabolic and Pharmacologic Adipose Remodeling With Enhanced Incretin AgonisTs | Semaglutide, Tirzepatide Metabolic syndrome, Obesity / overweight | BMI ≥27 | Not applicable | Recruiting | 1 | Sep 2028 | — | |
| NCT07619508Tirzepatide vs Semaglutide in Individuals at Cardiovascular Risk But Without Diabetes. | Semaglutide, Tirzepatide Cardiovascular disease, Obesity / overweight | BMI ≥25 | — | Active, not recruiting | 1 | Jun 2026 | — | |
| NCT07619989Transcutaneous Auricular Vagus Nerve Stimulation for Poor Weight-Loss Response to Incretin Receptor Agonists | Tirzepatide Obesity / overweight | — | Not applicable | Recruiting | 1 | Jul 2026 | — | |
| NCT03375463A Study of Tirzepatide (LY3298176) in Healthy Participants | Tirzepatide Healthy volunteers | BMI 18.5-32 | Ph 1 | Completed | 1 | Dec 2018 | — | results |
| NCT04004988A Study of Tirzepatide Administered by Two Different Devices in Healthy Participants | Tirzepatide Healthy volunteers | BMI 18-32 | Ph 1 | Completed | 1 | Dec 2019 | — | results |
| NCT04050553A Study of Tirzepatide in Participants With Type 2 Diabetes Mellitus | Tirzepatide Type 2 diabetes | BMI 23-45 | Ph 1 | Completed | 1 | Jan 2022 | 1 | results |
| NCT04050670A Study of Tirzepatide at Different Injection Sites in Participants With Different Body Sizes | Tirzepatide Healthy volunteers, Obesity / overweight | BMI 18.5-45 | Ph 1 | Completed | 1 | Apr 2020 | — | results |
| NCT04081337A Study to Measure Energy Expenditure and Food Intake in Participants With Obesity Using Tirzepatide | Tirzepatide Obesity / overweight | BMI 30-45 | Ph 1 | Completed | 1 | May 2022 | — | results |
| NCT04172987A Study of the Effect of Tirzepatide on How the Body Handles Birth Control Pills in Healthy Female Participants | Tirzepatide Healthy volunteers | BMI ≥18.5 | Ph 1 | Completed | 1 | Feb 2021 | — | results |
| NCT04311424Study of Tirzepatide in Healthy Participants | Tirzepatide Healthy volunteers | BMI 18-32 | Ph 1 | Completed | 1 | Oct 2020 | — | results |
| NCT04407234A Study to Measure Stomach Emptying in Overweight Non-diabetic and Diabetic Participants Using Tirzepatide | Tirzepatide Obesity / overweight, Type 2 diabetes | BMI 27-45 | Ph 1 | Completed | 1 | Jan 2021 | — | results |
| NCT05582096A Study of LY3457263 in Obese Participants | Tirzepatide Obesity / overweight | BMI 27-45 | Ph 1 | Completed | 1 | Jun 2023 | — | |
| NCT05751720Effect on Non-Alcoholic Fatty Liver Disease in Patients With Type 2 Diabetes Mellitus With Gastric Inhibitory Polypeptide/Glucagon Like Peptide-1 Analogue | Semaglutide, Tirzepatide MASH / NAFLD / liver fibrosis, Type 2 diabetes | BMI ≥19 | Ph 1/2 | Unknown | 1 | Oct 2024 | 2 | |
| EXPEND-FURole Of Metabolic Adaptation In Weight Regain | Tirzepatide Obesity / overweight | — | — | Completed | 1 | May 2024 | — | |
| NCT05978713A Study of Tirzepatide (LY3298176) in Healthy Lactating Females | Tirzepatide Healthy volunteers | BMI 18.5-40 | Ph 1 | Completed | 1 | Mar 2024 | — | results |
| NCT05990374Therapeutic Effects and Effects on Body Fat of GLP-1 Receptor Agonists in Patients With Type 2 Diabetes for 1-4 Years | Dulaglutide, Semaglutide, Tirzepatide Obesity / overweight, Type 2 diabetes | BMI ≥24 | Not applicable | Unknown | 1 | Jan 2024 | 1 | |
| TRZEffects of Tirzepatide Plus Intensive Lifestyle Therapy on Body Weight and Metabolic Health in Latinos With Obesity | Tirzepatide Obesity / overweight | BMI 30-42 | Ph 4 | Withdrawn | 1 | May 2024 | — | |
| NCT06605703A Randomized Controlled Trial Comparing the Effectiveness of Different Treatment Options for Weight Management After Discontinuation of Semaglutide and Tirzepatide (GLP1 Transition Trial) | Semaglutide, Tirzepatide Obesity / overweight | BMI ≥30 | Ph 4 | Completed | 1 | Feb 2026 | — | |
| NCT06640972Effects of RDX-002 on Postprandial Triglycerides in Patients Discontinuing GLP-1 Agonists | Semaglutide, Tirzepatide Obesity / overweight | HbA1c ≤6.5% | Ph 2 | Completed | 1 | Jan 2025 | — | |
| COSMOS-DIGITALA Study to Determine the Feasibility of Online Recruitment of People Using an Anti-Obesity Medication for Weight Loss | Semaglutide, Tirzepatide Obesity / overweight | — | — | Completed | 1 | Jan 2025 | — | |
| NCT06779929Comparative Study of Tirzepatide Versus Dulaglutide (SURPASS CVOT) or Semaglutide on Major Cardiovascular Events in Participants With Type 2 Diabetes | Dulaglutide, Semaglutide, Tirzepatide Cardiovascular disease, Type 2 diabetes | Established ASCVD | — | Completed | 1 | Dec 2025 | 1 | |
| TIRTLE2Acute Metabolic Effects of Tirzepatide in Type 1 Diabetes | Tirzepatide Obesity / overweight, Type 1 diabetes | BMI ≥27 | Ph 2 | Not yet recruiting | 1 | Dec 2027 | 1 | |
| DUP-TIRZSEMAComparative Effectiveness of Tirzepatide Versus Semaglutide in Individuals With Heart Failure With Preserved Ejection Fraction | Semaglutide, Tirzepatide Heart failure, Obesity / overweight, Type 2 diabetes | BMI ≥27 | — | Completed | 1 | Jun 2025 | 1 | |
| DUP-SUMMITEmulation of the SUMMIT Heart Failure Trial in Healthcare Claims Data | Tirzepatide Heart failure, Obesity / overweight, Type 2 diabetes | BMI ≥27 | — | Completed | 1 | Jun 2025 | 1 | |
| DUP-SURPASSPrediction of the SURPASS-CVOT Cardiovascular Outcome Trial in Healthcare Claims Data | Dulaglutide, Tirzepatide Cardiovascular disease, Type 2 diabetes | BMI ≥25 | — | Completed | 1 | Jul 2025 | 1 | |
| TIRZSEMA-CVOTComparative Effectiveness of Tirzepatide and Semaglutide in Individuals at Cardiovascular Risk | Dulaglutide, Semaglutide, Tirzepatide Cardiovascular disease, Obesity / overweight, Type 2 diabetes | BMI ≥25 | — | Completed | 1 | Jul 2025 | 1 | |
| NCT07203677Comparative Effectiveness of Tirzepatide Versus Sitagliptin in Individuals at Cardiovascular Risk (TIRZSITA-CVOT) | Tirzepatide Cardiovascular disease, Type 2 diabetes | BMI ≥25 | — | Completed | 1 | Oct 2025 | — | |
| NCT07368855GLP-1 Medicines and Mental Health Changes | Semaglutide, Tirzepatide Obesity / overweight | — | Not applicable | Completed | 1 | Jul 2025 | — | |
| TIR-REALReal-World Tirzepatide Therapy in Post-Bariatric Weight Regain and Preoperative Obesity Patients | Tirzepatide Bariatric Surgery, Bariatric Surgery Candidate, Obesity / overweight | — | — | Completed | 1 | Jan 2026 | — | |
| NCT05553093Effects of Tirzepatide and Insulin Glargine on Glucolipid Metabolism and Brain Function in Patients With Type 2 Diabetes | Tirzepatide Obesity / overweight, Type 2 diabetes | BMI ≥23 | Ph 4 | Recruiting | 1 | Dec 2023 | — | |
| NCT05659368Tirzepatide Monotherapy in Patients With Wolfram Syndrome Type 1 | Tirzepatide Diabetes (other / unspecified), Wolfram Syndrome | — | Ph 2 | Unknown | 1 | Oct 2024 | — | |
| NCT06890611A Study of Bimagrumab Alone (LY3985863) and Bimagrumab With Tirzepatide (LY900042) in Healthy Participants | Tirzepatide Healthy volunteers | BMI 22-30 | Ph 1 | Completed | 1 | Sep 2025 | — | |
| NCT07107334A Study to Estimate Early Clinical Efficacy Signals of GLP-1 Agonist Administration in Conjunction With Levonorgestrel Intrauterine Device in Obese Patients With Endometrioid Intraepithelial Neoplasia | GLP-1 / incretin class catch-all, Liraglutide, Semaglutide, Tirzepatide Obesity / overweight, Oncology | BMI ≥30 | Ph 2 | Recruiting | 1 | Nov 2028 | — | |
| NCT07220473Tirzepatide to Slow Biological Aging | GLP-1 / incretin class catch-all, Tirzepatide Obesity / overweight | BMI ≥30 | Ph 2 | Recruiting | 1 | Nov 2027 | — | |
| NCT07398222Gastric Content in Fasting Volunteers and in Tirzepatide Users: an Observational and Cross-sectional Study | Tirzepatide Healthy volunteers, Perioperative / gastric aspiration risk | — | — | Recruiting | 1 | Mar 2026 | — | |
| NCT07559500Tirzepatide s Dopaminergic Effects in Alcohol Use Disorders (AUD) | Tirzepatide Alcohol / substance use, Healthy volunteers | — | Ph 1 | Recruiting | 1 | Dec 2031 | — | |
| OPTI-OAGBPreoperative Optimization With Tirzepatide, Ketogenic Diet, or Standard Care Before One Anastomosis Gastric Bypass Surgery | Tirzepatide Bariatric Surgery Candidate, Obesity / overweight | BMI 40-55 | — | Not yet recruiting | 1 | Jul 2029 | — | |
| TEAR-AF-HFpEFTirzepatide on Atrial Fibrillation Recurrence After Catheter Ablation in Patients With Obesity and HFpEF | Tirzepatide Atrial fibrillation, Heart failure, Obesity / overweight | BMI ≥28 | Ph 4 | Not yet recruiting | 1 | Aug 2029 | — | |
| NCT07633639GLP-1 Therapy After Bariatric Surgery in Chinese Patients With Obesity | Mazdutide, Semaglutide, Tirzepatide Bariatric Surgery, Obesity / overweight | BMI ≥30 | Not applicable | Recruiting | 1 | May 2028 | — | |
| NCT07635953New Triple Combination Therapy in Newly Diagnosed Type 2 Diabetes | Tirzepatide Obesity / overweight, Type 2 diabetes | BMI ≥24 | Ph 3 | Not yet recruiting | 1 | Jul 2029 | — | |
| NCT07638592Tirzepatide-Based Prehabilitation Before Elective Ventral and Incisional Hernia Repair in Patients With Obesity | Tirzepatide Obesity / overweight | BMI ≥30 | — | Completed | 1 | Jun 2026 | — | |
| NCT07640139Estimating the Impact of Obesity Medications on Clinical and Economic Outcomes | Tirzepatide Obesity / overweight | BMI ≥30 | — | By invitation | 1 | Dec 2029 | — | |
| DiagenixPrecision Obesity Medicine: Genetic Prediction of Response to GLP-1/GIP Agonists. | Semaglutide, Tirzepatide Obesity / overweight | BMI ≥40 | — | Recruiting | 1 | Jan 2027 | 8 | |
| WE-FiERCEWeight-loss Drug for Fertility-Sparing Treatment of Atypical Hyperplasia and Low-grade Cancer of the Endometrium | Tirzepatide Obesity / overweight, Oncology, Reproductive / infertility | BMI ≥27 | Ph 2 | Not yet recruiting | 0 | Feb 2027 | — | |
| TZP-T1DTirzepatide for the Treatment of Concurrent Type 1 Diabetes and Overweight or Obesity | Tirzepatide Obesity / overweight, Type 1 diabetes | BMI ≥27 | Ph 2 | Not yet recruiting | 0 | Dec 2028 | 1 | |
| NCT06856928Impact of Antiobesity Medications on Appetite and Appetite-related Hormones and Metabolites. | Semaglutide, Tirzepatide Obesity / overweight | BMI 30-45 | — | Not yet recruiting | 0 | Dec 2026 | — | |
| PRIMEImpact of Protein Supplementation and Resistance Training on Body Composition, Functional Parameters, Metabolic Adaptation, and Nitrogen Balance in Adults Aged 45 Years and Older With Overweight or Obesity Receiving Incretin-based Medications | Semaglutide, Tirzepatide Obesity / overweight | BMI ≥30 | Not applicable | Not yet recruiting | 0 | Jul 2028 | — | |
| NCT07179120Can Fat-Burning Shots Boost Fertility? Comparing Weight-Loss Injections vs. Healthy Habits for Obese Men With Low Sperm Health | GLP-1 / incretin class catch-all, Semaglutide, Tirzepatide Obesity / overweight, Reproductive / infertility | BMI ≥28 | Ph 2 | Not yet recruiting | 0 | Aug 2026 | — | |
| TEACHEffect of Tirzepatide on Cardiovascular and Metabolic Parameters in Obese Adult Patients With Congenital Heart Disease | Tirzepatide Cardiovascular disease, Obesity / overweight | — | Ph 4 | Not yet recruiting | 0 | Jun 2027 | — | |
| NCT07382388A Real-World Study on the Impact of Weight Loss on Treatment Efficacy in Overweight/Obese Patients With Plaque Psoriasis | GLP-1 / incretin class catch-all, Semaglutide, Tirzepatide Obesity / overweight, Psoriasis / psoriatic arthritis | — | — | Not yet recruiting | 0 | Dec 2027 | — | |
| NCT07527910A Phase 2a Study of ALN-PNP With and Without a GLP1R Agonist in Adult Patients With Homozygous PNPLA3-Related MASLD | Tirzepatide MASH / NAFLD / liver fibrosis, Obesity / overweight | BMI 30-45 | Ph 2 | Not yet recruiting | 0 | Nov 2029 | — | |
| NCT07554638Incretin Therapies in Obesity-related HFpEF | Tirzepatide Heart failure, Obesity / overweight | BMI ≥30 | Ph 4 | Not yet recruiting | 0 | Apr 2029 | — | |
| TiTRETirzepatide Titration to Reduce Side Effects in Individuals With Obesity | Tirzepatide Obesity / overweight | BMI ≥27 | Not applicable | Not yet recruiting | 0 | May 2029 | — | |
| NCT07609160Effectiveness of Combined GLP-1/GIP Dual Agonist Therapy and Structured Exercise on Skeletal Muscle Morphology, Quality, and Physical Function in Overweight and Obese Individuals | GLP-1 / incretin class catch-all, Tirzepatide Obesity / overweight | BMI ≥27 | Not applicable | Not yet recruiting | 0 | Nov 2027 | — | |
| NCT05812183Gastric Sleeve-Induced Weight Loss on Shortness of Breath in Obesity | Liraglutide, Semaglutide, Tirzepatide Bariatric Surgery, Obesity / overweight | — | Ph 4 | Withdrawn | 0 | Feb 2025 | — | |
| NCT06354101The Purpose of This Registry Study is to Learn More About Metabolic Health: Approximately 15,000 Participants Who Are Overweight or Have Obesity With or Without Metabolic Diseases Are Expected to Participate in This Registry Study. | Semaglutide, Tirzepatide Obesity / overweight | — | — | Withdrawn | 0 | Jul 2023 | — | |
| NCT06301256Evaluate the Efficacy of TIRZEPATIDE for the Treatment of Moderate to Severe HS Hidradenitis Suppurativa | Tirzepatide Obesity / overweight | — | Not applicable | Unknown | 0 | Mar 2025 | — | |
| REBUILDResearch on Effects of Drugs on Body Composition and Function With Imaging in Diabetes | Semaglutide, Tirzepatide Type 2 diabetes | — | — | Not yet recruiting | 0 | Oct 2027 | — | |
| NCT07265752Tirzepatide for the Treatment of Cannabis Use Disorder | Tirzepatide Alcohol / substance use | — | Ph 2 | Not yet recruiting | 0 | Jun 2028 | — | |
| NCT07468552Trial of Tirzepatide for the Treatment of Cannabis Use Disorder | Tirzepatide Alcohol / substance use | — | Ph 2 | Not yet recruiting | 0 | Mar 2028 | — | |
| TREAT-ECTirzepatide in the Treatment of Endometrial Cancer | Tirzepatide Obesity / overweight, Oncology | BMI ≥27 | Ph 2 | Not yet recruiting | 0 | Jan 2028 | — | |
